Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
4.575
+0.065 (1.44%)
Oct 8, 2025, 11:54 AM EDT - Market open
Alumis Employees
As of December 31, 2024, Alumis had 170 total employees, including 168 full-time and 2 part-time employees. The number of employees increased by 61 or 55.96% compared to the previous year.
Employees
170
Change (1Y)
61
Growth (1Y)
55.96%
Revenue / Employee
$117,971
Profits / Employee
-$1,338,341
Market Cap
476.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170 | 61 | 55.96% |
| Dec 31, 2023 | 109 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALMS News
- 21 days ago - Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript - Seeking Alpha
- 5 weeks ago - Alumis to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 7 weeks ago - Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - GlobeNewsWire
- 3 months ago - Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 4 months ago - Alumis to Present at the Jefferies Global Healthcare Investor Conference - GlobeNewsWire
- 4 months ago - Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis - GlobeNewsWire
- 5 months ago - Alumis Completes Merger with ACELYRIN - GlobeNewsWire